By Andrea Shalal, Maggie Fick and Alistair Smout

Summary:

– Britain will raise prices paid for new U.S. medicines by 25%.

– UK-made drugs and medical tech gain exemption from Section 232 and 301 tariffs .

– NICE value appraisal framework will increase, boosting access to innovative medicines.

WASHINGTON/LONDON — The United States and Britain announced a deal on Monday to secure zero tariff s on British pharmaceutical products and medical technology in return for Britain spending more on medicines and overhauling how it values drugs.

Under the agreement, Britain will raise the net price it pays for new U.S. medicines by 25%. In return, UK-made medicines, drug ingredients and medical technology will be exempt from Section 232 sectoral tariff s and a

See Full Page